BioCryst Pharmaceuticals (NASDAQ:BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results.
Similarly Is BCRX a buy? Out of 6 analysts, 2 (33.33%) are recommending BCRX as a Strong Buy, 2 (33.33%) are recommending BCRX as a Buy, 2 (33.33%) are recommending BCRX as a Hold, 0 (0%) are recommending BCRX as a Sell, and 0 (0%) are recommending BCRX as a Strong Sell. What is BCRX’s earnings growth forecast for 2022-2024?
What is the target price for BCRX stock? Stock Price Target
| High | $30.00 |
|---|---|
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
5 days ago
Additionally, What does BioCryst Pharma do?
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
When did BCRX go public?
When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
Who owns BioCryst Pharmaceuticals? State Street Global Advisors, Inc. is currently the largest shareholder, with 10% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.0% of common stock, and Baker Bros. Advisors LP holds about 7.2% of the company stock.
Where is BioCryst located? BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.
How many employees does BioCryst have? BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina.
How many shares does BioCryst have?
BioCryst Pharmaceuticals, Inc. (US:BCRX) has 429 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 134,860,198 shares. Largest shareholders include BlackRock Inc., Baker Bros.
Is BioCryst a good company? BioCryst Pharmaceuticals has an overall rating of 3.9 out of 5, based on over 10 reviews left anonymously by employees. 65% of employees would recommend working at BioCryst Pharmaceuticals to a friend and 62% have a positive outlook for the business.
